What It Is
Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH).
GHRH is produced in the hypothalamus, a small region of the brain responsible for regulating hormones, metabolism, sleep cycles, and energy balance.
Its job is simple but powerful:
signal the pituitary gland to release growth hormone (GH).
Tesamorelin mimics this signal, encouraging the body to produce its own natural growth hormone pulses rather than supplying external hormone directly.
This is why Tesamorelin is categorized as a growth hormone secretagogue.
Unlike injecting growth hormone itself, Tesamorelin works by stimulating the body’s existing endocrine pathway, allowing GH release to remain regulated by normal biological feedback systems.
Tesamorelin is one of the few peptides in this category with significant human clinical research and is FDA-approved for the reduction of visceral abdominal fat in HIV-associated lipodystrophy.
Key Benefits
Visceral Fat Reduction
Tesamorelin is best known for its effect on visceral fat, the deep abdominal fat stored around internal organs.
Visceral fat is associated with:
• insulin resistance
• metabolic dysfunction
• cardiovascular risk
• chronic inflammation
By increasing growth hormone signaling, Tesamorelin may help reduce this metabolically harmful fat depot.
Improved Body Composition
Growth hormone plays an important role in regulating fat metabolism and lean tissue maintenance.
Potential effects include:
• increased fat oxidation
• improved lean body mass
• enhanced metabolic efficiency
Tesamorelin does not act as a direct fat burner but instead shifts the hormonal environment that influences body composition.
Sleep and Recovery Support
Growth hormone release naturally occurs during deep sleep cycles.
By supporting GH signaling, Tesamorelin may indirectly support:
• recovery processes
• tissue repair
• sleep-related regeneration
Cognitive and Brain Health
Growth hormone and IGF-1 signaling influence brain function.
Emerging research suggests potential roles in:
• cognitive function
• neuronal repair
• brain metabolism
This area of research is still evolving.
Typical Reconstitution Example (2.5 mL Standard)
Example vial: 10 mg Tesamorelin
Add 2.5 mL bacteriostatic water
Resulting concentration:
10 mg ÷ 2.5 mL = 4 mg per mL
Using a standard insulin syringe:
100 units = 1 mL
Approximate dosing conversions:
1 mg dose ≈ 25 units
Typical Dosing Strategy
A commonly used dose in research and clinical contexts:
1 mg daily
Some protocols use:
• 1 mg daily
• occasionally 2 mg daily depending on protocol
Consistency is important because GH signaling works through pulsatile endocrine rhythms rather than immediate pharmacologic effects.
Injection Timing
Tesamorelin is typically injected once daily.
Evening (Most Common)
Evening injections are often preferred because natural growth hormone secretion peaks during early sleep cycles.
Administering Tesamorelin before bedtime may align with the body’s natural GH rhythm.
Morning
Some individuals prefer morning injections for routine consistency.
However, evening dosing is generally favored in many protocols.
Injection Frequency
Typical protocols include:
• once daily injection
• long-term protocols ranging from 3–6 months
Because visceral fat reduction occurs gradually, consistent long-term use is often necessary.
Best Peptide Stacks
Tesamorelin + Ipamorelin
This combination stimulates growth hormone release through two complementary pathways.
Tesamorelin
→ stimulates GHRH receptors
Ipamorelin
→ stimulates ghrelin receptors on the pituitary
Together they may enhance natural GH pulsatility.
Tesamorelin + CJC-1295
CJC-1295 extends the half-life of GHRH signaling, potentially prolonging GH stimulation.
This pairing is often used in protocols focused on body composition and recovery.
Support Supplements
Supporting metabolic health can enhance the effects of GH signaling.
Useful additions include:
Magnesium
Supports sleep quality and hormone regulation.
Vitamin D
Supports endocrine and metabolic health.
Protein-rich nutrition
Supports lean tissue maintenance.
Omega-3 fatty acids
Help regulate inflammation and metabolic signaling.
Expected Timeline
Growth hormone-mediated body composition changes occur gradually.
Typical observations include:
4–6 weeks
Early metabolic improvements may begin.
8–12 weeks
Noticeable changes in visceral fat and body composition.
3–6 months
More significant reductions in abdominal fat.
Ideal Use Cases
• visceral abdominal fat reduction
• metabolic health support
• body recomposition programs
• age-related decline in growth hormone signaling
